Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. März 2007 08:00 ET | Quelle: Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals Advances Difimicin Into Phase 3 Clinical Trial

SAN DIEGO, March 14, 2007 (PRIME NEWSWIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today reported that the U.S. Food and Drug Administration has agreed with the recommendation of the...
27. Februar 2007 08:00 ET | Quelle: Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals Regains North American Rights to Difimicin (Par-101/Opt-80)

SAN DIEGO, Feb. 27, 2007 (PRIME NEWSWIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced today that the company has regained North American rights to Difimicin (PAR-101/OPT-80) from Par...
21. Februar 2007 08:00 ET | Quelle: Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option by Underwriters

SAN DIEGO, Feb. 21, 2007 (PRIME NEWSWIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced today that the underwriters of the company's recent initial public offering of common stock have...
09. Februar 2007 08:00 ET | Quelle: Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals, Inc. Announces Pricing For Initial Public Offering

SAN DIEGO, Feb. 9, 2007 (PRIME NEWSWIRE) -- Optimer Pharmaceuticals, Inc. announced today the initial public offering of 7,000,000 shares of its common stock at a price of $7.00 per share. The common...